drugset

Drugs / ACM-001.1

Follow last change Jun 2025 re-read 2 minutes ago

ACM-001.1

also known as S-Pindolol Benzoate

Developed for: muscular atrophy
Investigated by: Actimed Therapeutics Ltd · Quotient Sciences

Trials 1 · a red edge is where a trial was stopped

today NCT06028321 · Ph 1

20222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT06028321	Nov 2021 → Jun 2022	hypoproteinemia, hypercatabolic	Actimed Therapeutics Ltd	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT07101939 Comparator	Jun 2025 → Mar 2027 expected	muscular atrophy, obesity disorder	Actimed Therapeutics Ltd	Recruiting	No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	ACM-001.1	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06028321 ↗
Known as	S-Pindolol Benzoate	“Pharmacokinetics, Pharmacodynamics and Bioavailability of ACM-001.1 (S-Pindolol Benzoate) in Healthy Volunteers.” PMID 39665235 ↗ Dec 2024 1 NCT07101939 ↗
Action	Activate	“increased anabolism through partial β2 receptor agonism” PMID 39665235 ↗ Dec 2024
Route	Oral	“ACM-001.1 immediate release tablets for oral use” NCT06028321 ↗